natgillin/translations-raw huggingface dataset:
A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of 25 months, has not shown Enbrel to be an effective treatment for Wegener’s granulomatosis.
S placebom nadzorovano preskušanje, v katerem je 89 odraslih bolnikov poleg standardnega zdravljenja (vključno s ciklofosfamidom ali metotreksatom in glukokortikoidi) jemalo zdravilo Enbrel z medianim časom zdravljenja 25 mesecev, ni pokazalo učinkovitosti zdravila Enbrel za zdravljenje Wegenerjeve granulomatoze.
A placebo-controlled trial, in which 89 adult patients were treated with etanercept in addition to standard therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of 25 months, has not shown etanercept to be an effective treatment for Wegener’s granulomatosis.
S placebom nadzorovano preskušanje, v katerem je 89 odraslih bolnikov poleg standardnega zdravljenja (vključno s ciklofosfamidom ali metotreksatom in glukokortikoidi) jemalo etanercept z medianim časom zdravljenja 25 mesecev, ni pokazalo učinkovitosti etanercepta za zdravljenje Wegenerjeve granulomatoze.
A placebo-controlled, randomized, single-dose, crossover study to evaluate the effect on the QT interval of healthy volunteers was conducted with three oral doses of voriconazole and ketoconazole.
S placebom nadzorovana, randomizirana, navzkrižna študija z enkratnim odmerkom, ki je ocenjevala vpliv na interval QTc, je bila izvedena s tremi peroralnimi odmerki vorikonazola in ketokonazola pri zdravih prostovoljcih.
A planned interim analysis (with 400 patients enrolled) showed a low likelihood of demonstrating a significant difference in the primary endpoint of “Composite Time to Complete Organ Failure Resolution” (CTCOFR score of 9.8 versus 9.7 mean days over 14 days).
Načrtovana vmesna analiza (s 400 sodelujočimi) je pokazala majhno verjetnost za statistično značilno razliko pri cilju študije “čas do izboljšanja po popolni odpovedi organov” (CTCOFR (Composite Time to Complete Organ Failure Resolution ) rezultat –; 9,8 proti 9,7 povprečnih dni v obdobju 14 dni).
A planned interim analysis of OS was conducted at the time of the PFS analysis and did not reach the interim boundary for statistical significance (HR=0.68 [0.51, 0.90], p=0.006).
Načrtovana vmesna analiza OS je bila opravljena v času analize PFS in ni dosegla vmesne meje za statistično značilnost (HR = 0,68 [0,51; 0,90], p = 0,006).
a planned surgery (including dental) in the next seven days
načrtovan kirurški poseg (tudi na zobeh) v naslednjih sedmih dneh,
a planned surgery (including dental) in the next seven days
načrtovan kirurški poseg (tudi na zobeh) v naslednjih sedmih dneh;
a planned surgery (including dental) in the next seven days
načrtovan kirurški poseg (vključno na zobeh) v naslednjih 7 dneh
a planned surgery (including dental) in the next seven days.
načrtovan kirurški poseg (tudi na zobeh) v naslednjih sedmih dneh;
a planned surgery (including dental) in the next seven days.
načrtovan kirurški poseg (vključno na zobeh) v naslednjih 7 dneh
a planned surgery (including dental) in the next seven days.
načrtovan kirurški poseg (vključno na zobeh) v naslednjih 7 dneh;
a planned surgery (including dental) in the next seven days.
načrtovan kirurški poseg (vključno z zobozdravstvenimi posegi) v naslednjih sedmih dneh,
a planned surgery (including dental) in the next seven days.
nedaven kirurški poseg (vključno na zobeh). načrtovan kirurški poseg (vključno na zobeh) v naslednjih 7 dneh.
A planned surgical procedure within the next 30 days.
načrtovan kirurški poseg v naslednjih 30 dneh;
a plaque building up inside your arteries which could lead to heart attack and stroke;
nastajanje plakov v vaših arterijah, ki bi lahko vodili do srčnega infarkta in možganske kapi;
A plastic measuring jug (in the medicine pack)
plastično merilno čašo (v pakiranju),
A plastic measuring syringe is included for measuring the correct dose.
Za pravilno odmerjanje je priložena plastična merilna brizga.
a platelet count > 1000 x 109/l or a history of thrombo-haemorrhagic events.
število krvnih ploščic, ki je višje od 1000 x 109/l, ali že doživeti trombohemoragični primeri.
A Plunger
A bat
a plunger rod
nosilec za bat brizge
a Plus background regimen of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg fixed-dose combination b Missing = excluded analysis
a Plus osnovi režim s fiksno kombinacijo emtricitabina 200 mg in dizoproksiltenofovirata fumarata 300 mg b Manjka = izključena analiza
A polar fraction proposed to be serine derivatives accounted for approximately 20% in urine, but was detected only in small amounts (0-2%) in human plasma of some subjects.
Polarna frakcija, ki jo verjetno sestavljajo derivati serina, predstavlja približno 20 % odmerka, izločenega s sečem, v človeški plazmi pa so jo v majhnih količinah (0–2 %) določili pri nekaterih preiskovancih.
A polycarbonate Robertsite vial adaptor (allowing needleless luer connection to the vial).
Polikarbonaten adapter Robertsite za viale (ki omogoča brezigelni luer priključek na vialo)
A polystyrene resin / polyurethane carry case (shuttle) which can hold 3 capsules is included in each pack.
Škatlica iz polistirenske smole / škatlica za prenos iz poliuretana (shuttle), v kateri lahko nosite s seboj 3 kapsule, je priložena v vsakem pakiranju.
A polystyrene resin/polyurethane carry case (shuttle) which can hold 3 tablets is included in each pack.
Škatlica iz polistirenske smole / škatlica za prenos iz poliuretana (shuttle), v kateri lahko nosite s seboj 3 tablete, je priložena v vsakem pakiranju.
A pooled analysis of five efficacy studies*, showed a 71.4% (95% CI:20.1;91.1) efficacy against severe rotavirus gastro-enteritis (Vesikari score 11) caused by rotavirus G2P[4] genotype during the first year of life.
Združena analiza petih študij* kaže, da je bila med prvim letom življenja učinkovitost proti hudemu rotavirusnemu gastroenteritisu (Vesikari ≥ 11), ki ga povzroča genotip G2P[4] rotavirusa 71,4- odstotna (95 % IZ: 20,1; 91,1).
A pooled analysis of five efficacy studies*, showed a 71.4% (95% CI:20.1;91.1) efficacy against severe rotavirus gastro-enteritis (Vesikari score 11) caused by rotavirus G2P[4] genotype during the first year of life.
Združena analiza petih študij* kaže, da je bila med prvim letom življenja učinkovitost proti hudemu rotavirusnemu gastroenteritisu (Vesikari ≥ 11), ki ga povzroča genotip G2P[4] rotavirusa 71,4-odstotna (95 % IZ: 20,1; 91,1).
A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator-controlled, double-blind clinical trials in over 8,100 patients in the pioglitazone-treated groups and 7,400 in the comparator-treated groups of up to 3.5 years duration.
Izvedena je bila združena analiza neželenih učinkov v obliki zlomov kosti iz randomiziranih, s primerjalnim zdravilom nadzorovanih, dvojno slepih kliničnih preskušanj, ki so trajala do 3,5 let in zajela več kot 8.100 bolnikov, ki so se zdravili s pioglitazonom, in 7.400 bolnikov, ki so se zdravili s primerjalnim zdravilom.
A pooled population pharmacokinetic analysis indicates that the Ebilfumin dosage regimen described in Section 4.2 Posology and method of administration results in lower exposure (30% on average across all trimesters) to the active metabolite in pregnant women compared to non-pregnant women.
Populacijska farmakokinetična analiza združenih podatkov kaže, da režim odmerjanja Ebilfumin, opisan v poglavju 4.2 Odmerjanje in način uporabe, vodi v manjšo izpostavljenost aktivnemu presnovku (30 % v povprečju v vseh trimesečjih) pri nosečnicah v primerjavi z ženskami, ki niso noseče.
A pooled population pharmacokinetic analysis indicates that the Ebilfumin dosage regimen described in Section 4.2 Posology and method of administration results in lower exposure (30% on average across all trimesters) to the active metabolite in pregnant women compared to non-pregnant women.
Populacijska farmakokinetična analiza združenih podatkov kaže, da režim odmerjanja oseltamivirja, opisan v poglavju 4.2 Odmerjanje in način uporabe, vodi v manjšo izpostavljenost aktivnemu presnovku (30 % v povprečju v vseh trimesečjih) pri nosečnicah v primerjavi z ženskami, ki niso noseče.
A pooled population pharmacokinetic analysis indicates that the Tamiflu dosage regimen described in Section 4.2 Posology and method of administration results in lower exposure (30% on average across all trimesters) to the active metabolite in pregnant women compared to non-pregnant women.
Populacijska farmakokinetična analiza združenih podatkov kaže, da režim odmerjanja zdravila Tamiflu, opisan v poglavju 4.2 Odmerjanje in način uporabe, vodi v manjšo izpostavljenost aktivnemu presnovku (30 % v povprečju v vseh trimesečjih) pri nosečnicah v primerjavi z ženskami, ki niso noseče.
A popping noise or popping sensation in the penis, sometimes described as “snapping” or “cracking” and sometimes accompanied by detumescence, haematoma and/or pain, were reported in 73/551 (13.2%) Xiapex-treated patients and 1/281 (0.3%) placebo-treated patients, in Studies 1 and 2 combined.
Pri 73/551 (13,2 %) bolnikov, zdravljenih z zdravilom Xiapex, in pri 1/281 (0,3 %) bolnikov, zdravljenih s placebom, se je v študiji 1 in 2 skupaj pojavil pokajoč zvok ali pokajoč občutek v penisu, včasih opisan kot "tleskanje" ali "pokanje", ki so ga včasih spremljali detumescenca, hematom in/ali bolečina.
a popping sound or sensation in an erect penis
pokajoč zvok ali občutek v penisu med erekcijo
A population analysis of the available data has found no evidence that patient weight affects olaparib plasma concentrations.
Populacijska analiza dostopnih podatkov ni pokazala, da bi telesna masa bolnice vplivala na koncentracijo olapariba v plazmi.
A population analysis of the available data has found no relationship between olaparib plasma concentrations and patient age.
Populacijska analiza dostopnih podatkov ni pokazala, da bi bila koncentracija olapariba v plazmi povezana z bolničino starostjo.
A population pharmacokinetic (PK) model was developed to analyse the PK data in 469 iNHL, 342 CLL and 130 DLBCL patients from Phase I, Phase II and Phase III studies who received obinutuzumab alone or in combination with chemotherapy.
Za analizo farmakokinetičnih podatkov pri 469 bolnikih z indolentnim ne-Hodgkinovim limfomom (iNHL), 342 bolnikih s KLL in 130 bolnikih z difuznim velikoceličnim limfomom B (DLBCL) v študijah I., II. in III. faze, ki so dobivali obinutuzumab sam ali v kombinaciji s kemoterapijo, je bil razvit populacijski farmakokinetični model.
A population pharmacokinetic analysis based on data with oral paliperidone prolonged release tablets showed a slightly lower exposure to paliperidone in smokers compared with non-smokers.
Analiza farmakokinetike populacije na podlagi podatkov za peroralni paliperidon v obliki tablet s podaljšanim sproščanjem je pokazala rahlo manjšo izpostavljenost paliperidonu pri kadilcih kot pri nekadilcih.
A population pharmacokinetic analysis conducted on all clinical data available suggests that the disposition of dinutuximab is not altered by age, race, gender, concomitant medications (IL-2, GM-CSF) and the presence of capillary leak syndrome, renal or hepatic impairment.
Farmakokinetična populacijska analiza, ki zajema vse klinično dosegljive podatke, kaže da starost, rasa, spol, spremljajoča zdravila (IL-2, GM-CSF), prisotnost sindroma kapilarnih razpok in odpoved ledvic ali jeter, ne vplivajo na razporeditev dinutuksimab.
A population pharmacokinetic analysis did not indicate clinically significant changes in the systemic exposure of denosumab at steady state with respect to age (18 to 87 years), race/ethnicity (Blacks, Hispanics, Asians and Caucasians explored), gender or solid tumour types.
Populacijska farmakokinetična analiza ni pokazala klinično pomembnih sprememb sistemske izpostavljenosti denosumabu v stanju dinamičnega ravnovesja glede na starost (od 18 do 87 let), raso/etnično pripadnost (raziskani črnci, hispani, azijci in belci), spol ali vrsto solidnega tumorja.
A population pharmacokinetic analysis for TOBI Podhaler in cystic fibrosis patients aged 6 to 66 years estimated the apparent serum clearance of tobramycin to be 14 litres/h.
Glede na analizo populacijske farmakokinetike zdravila TOBI Podhaler pri bolnikih s cistično fibrozo, ki so stari od 6 do 66 let, je ocenjeni navidezni očistek tobramicina iz seruma 14 litrov na uro.
A population pharmacokinetic analysis found that mild or moderate renal impairment did not have a significant effect on the apparent clearance (CL/F) of sonidegib, suggesting that dose adjustment is not necessary in patients with renal impairment (see section 5.2).
Rezultati populacijske farmakokinetične analize kažejo, da blaga ali zmerna okvara ledvic ne vpliva bistveno na navidezni očistek (CL/F) sonidegiba, kar pomeni, da pri bolnikih z okvaro ledvic prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
A population pharmacokinetic analysis has been performed in a cohort of 205 children adequately distributed with respect to bodyweight (3.5 to 62.5 kg), biological and diseases (malignant and non- malignant) characteristics, thus representative of the high heterogeneity of children undergoing HPCT.
Populacijska farmakokinetična analiza je bila izvedena na kohorti 205 otrokglede na telesno maso (3,6 do 62,5 kg) ter biološke in bolezenske značilnosti (maligne in ne maligne bolezni) in je zato reprezantativna za visoko heterogenost otrok, podvrženih HPTC.
A population pharmacokinetic analysis in patients with hypertension did not indicate any clinically relevant changes in the steady-state exposure (AUC) and Cmax of aliskiren, amlodipine and hydrochlorothiazide compared to the corresponding dual therapies.
Analiza populacijske kinetike pri bolnikih s hipertenzijo ni pokazala klinično pomembnih razlik v izpostavljenosti (AUC) in v Cmax aliskirena, amlodipina in hidroklorotiazida v stanju dinamičnega ravnovesja v primerjavi z odmerjanjem ustreznih zdravil s po dvema učinkovinama.
A population pharmacokinetic analysis including 111 patients who ranged from 1.0 to 27.4 years (including 18 patients 1 to less than 3 years of age with BSA 0.42 m2 to 0.74 m2) showed that BSA- normalised clearance is in general higher in younger patients.
Populacijska farmakokinetična analiza, ki je vključevala podatke 111 bolnikov v starosti od 1,0 do 27,4 leta (vključno z 18 bolniki, ki so bili stari od 1 leta do manj kot 3 leta in so imeli telesno površino od 0,42 m2 do 0,74 m2), je pokazala, da je na telesno površino normaliziran očistek pri mlajših bolnikih praviloma večji.
A population pharmacokinetic analysis indicates that mildly elevated bilirubin and/or AST levels (based on National Cancer Institute [NCI] classification) do not significantly affect trametinib oral clearance.
Populacijska farmakokinetična analiza kaže, da blago zvišanje bilirubina in/ali AST (po klasifikaciji NCI [National Cancer Institute]) ne vpliva pomembno na peroralni očistek trametiniba.
A population pharmacokinetic analysis of clearance versus creatinine clearance shows no trend for subjects with mild and moderate renal impairment.
Populacijska farmakokinetična analiza očistka proti očistku kreatinina pri bolnikih z blago in zmerno okvaro ledvic ni pokazala trenda.
A population pharmacokinetic analysis of sildenafil data from adult PAH patients in clinical trials including a 12 week study to assess the efficacy and safety of oral sildenafil 20 mg three times a day when added to a stable dose of bosentan (62.5 mg – 125 mg twice a day) indicated a decrease in sildenafil exposure with bosentan co-administration, similar to that observed in healthy volunteers (see sections 4.4 and 5.1).
Populacijska farmakokinetična analiza podatkov o sildenafilu pri odraslih bolnikih s PAH iz kliničnih preskušanj, vključno z 12-tedensko študijo za oceno učinkovitost in varnost peroralnega sildenafila 20 mg trikrat na dan, kadar so ga dodajali stabilnemu odmerku bosentana (62,5–125 mg dvakrat na dan), je pokazala zmanjšanje izpostavljenosti sildenafilu ob sočasni uporabi z bosentanom, kar je podobno ugotovitvam pri zdravih prostovoljcih (glejte poglavji 4.4 in 5.1).
A population pharmacokinetic analysis showed no effect of age on pharmacokinetics of plerixafor.
Populacijska farmakokinetična analiza je pokazala, da starost nima nobenega vpliva na farmakokinetiko pleriksaforja.
A population pharmacokinetic analysis showed no effect of gender on pharmacokinetics of plerixafor.
Populacijska farmakokinetična analiza je pokazala, da spol nima nobenega vpliva na farmakokinetiko pleriksaforja.
A population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% in patients with Alzheimer’s disease (n=75 smokers and 549 non- smokers) following rivastigmine oral capsule doses of up to 12 mg/day.
Analiza populacijske farmakokinetike je pokazala, da uporaba nikotina poveča očistek po peroralni uporabi za 23 % pri bolnikih z Alzheimerjevo boleznijo (n=75 kadilcev in 549 nekadilcev) po uporabi peroralnih kapsul rivastigmina v odmerkih do 12 mg/dan.
A population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% in patients with Alzheimer’s disease (n=75 smokers and 549 non- smokers) following rivastigmine oral capsule doses of up to 12 mg/day.
Analiza populacijske farmakokinetike je pokazala, da uporaba nikotina poveča očistek po peroralni uporabi za 23 % pri bolnikih z Alzheimerjevo boleznijo (n=75 kadilcev in 549 nekadilcev) po uporabi peroralnih kapsul zdravila rivastigmina v odmerkih do 12 mg/dan.
A population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% in patients with Alzheimer’s disease (n=75 smokers and 549 non-smokers) following rivastigmine oral capsule doses for up to 12 mg/day.
Rezultati populacijske farmakokinetične analize so pokazali, da pri bolnikih z Alzheimerjevo boleznijo (n=75 kadilcev in 549 nekadilcev) uporaba nikotina za 23 % poveča očistek rivastigmina pri peroralnem odmerjanju rivastigmina v kapsulah v odmerkih do 12 mg/dan.
A population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% in patients with Alzheimer’s disease (n=75 smokers and 549 non-smokers) following rivastigmine oral capsule doses of up to 12 mg/day.
Analiza populacijske farmakokinetike je pokazala, da uporaba nikotina poveča očistek po peroralni uporabi za 23 % pri bolnikih z Alzheimerjevo boleznijo (n=75 kadilcev in 549 nekadilcev) po uporabi peroralnih kapsul zdravila rivastigmina v odmerkih do 12 mg/dan.
A population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% in patients with Alzheimer’s disease (n=75 smokers and 549 non-smokers) following rivastigmine oral capsule doses of up to 12 mg/day.
Rezultati populacijske farmakokinetične analize so pokazali, da pri bolnikih z Alzheimerjevo boleznijo (n=75 kadilcev in 549 nekadilcev) uporaba nikotina za 23 % poveča očistek rivastigmina pri peroralnem odmerjanju rivastigmina v kapsulah v odmerkih do 12 mg/dan.
A population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% in patients with Alzheimer’s disease (n=75 smokers and 549 non-smokers) following rivastigmine oral capsule doses of up to 12 mg/day.
Rezultati populacijske farmakokinetične analize so pokazali, da pri bolnikih z Alzheimerjevo boleznijo (n=75 kadilcev in 549 nekadilcev) uporaba nikotina za 23% poveča očistek rivastigmina pri peroralnem odmerjanju rivastigmina v kapsulah v odmerkih do 12 mg/dan.
A population pharmacokinetic analysis showed that pharmacokinetics of umeclidinium bromide are similar between COPD patients 65 years and older and those younger than 65 years of age.
Analiza populacijske farmakokinetike je pokazala, da je farmakokinetika umeklidinijevega bromida pri bolnikih s KOPB, starih 65 let ali več, podobna kot pri mlajših od 65 let.
A population pharmacokinetic analysis showed that plasma trabectedin concentrations observed in the Japanese population at dose level 1.2 mg/m2 were equivalent to those obtained in the non-Japanese western population at 1.5 mg/m².
Populacijska farmakokinetična analiza je pokazala, da so bile koncentracije trabektedina v plazmi, izmerjene pri japonskih bolnikih ob velikosti odmerka 1,2 mg/m2, enakovredne tistim, ki so jih izmerili pri zahodnih populacijah nejaponskega porekla ob odmerku 1,5 mg/m2.
A population pharmacokinetic analysis was carried out after capecitabine treatment of 505 patients with colorectal cancer dosed at 1250 mg/m2 twice daily.
Populacijsko farmakokinetično študijo so opravili po zdravljenju 505 bolnikov s kolorektalnim rakom, ki so prejemali 1.250 mg/m2 kapecitabina dvakrat na dan.
A population pharmacokinetic analysis was conducted with data from 1507 patients with various types of advanced malignancies receiving ZALTRAP with or without chemotherapy.
Populacijska farmakokinetična analiza je bila opravljena s podatki 1507 bolnikov z različnimi vrstami napredovalih malignomov, ki so prejemali zdravilo ZALTRAP s kemoterapijo ali brez nje.
A population pharmacokinetic analysis was performed in 927 cancer patients (764 with NSCLC) receiving GIOTRIF monotherapy.
Populacijska farmakokinetična analiza je zajela 927 bolnikov z rakom (764 z NSCLC), ki so se zdravili z monoterapijo z zdravilom GIOTRIF.
A population pharmacokinetic analysis was performed with data from 481 patients across different clinical trials (phase I, II and III) with various types of advanced malignancies who had received Perjeta as a single agent or in combination at doses ranging from 2 to 25 mg/kg administered every 3 weeks as a 30-60 minutes intravenous infusion.
Populacijsko farmakokinetično analizo so izvedli iz podatkov 481 bolnikov, ki so sodelovali v različnih kliničnih preskušanjih (faze I, II in III) z različnimi oblikami napredovalih rakov in so prejeli zdravilo Perjeta samostojno ali v kombinaciji v odmerku od 2 do 25 mg/kg, danih v obliki 30 do 60 minutne infuzije vsake 3 tedne.
A population PK analysis estimated that concomitant treatment with other anti- epileptics known to be enzyme inducers (carbamazepine, phenytoin, phenobarbital, in various doses) decreased the overall systemic exposure of lacosamide by 25%.
S farmakokinetično analizo populacije so ocenili, da sočasno zdravljenje z drugimi antiepileptiki, ki so znani induktorji encimov (različni odmerki karbamazepina, fenitoina, fenobarbitala), zmanjša skupno sistemsko izpostavljenost lakozamida za 25 %.
A population PK analysis was performed to evaluate the effect of hepatic impairment as defined using the National Cancer Institute (NCI) criteria of hepatic dysfunction on the clearance of daratumumab based on pre-existing hepatic function data in 223 patients.
Analizo populacijske farmakokinetike za oceno vpliva okvare jeter na očistek daratumumaba so izvedli na podatkih prej pridobljenih izvidov jetrne funkcije pri 223 bolnikih (z opredelitvijo stopnje jetrne disfunkcije po kriterijih NCI - National Cancer Institute).
A population PK and PK/PD analysis was conducted with the scope to extrapolate the PK and key safety and efficacy endpoints of sunitinib in paediatric patients with GIST (age group 6-17 years).
Izvedena je bila analiza populacijske farmakokinetike in farmakokinetike/farmakodinamike z namenom ekstrapolacije farmakokinetike in ključnih opazovanih dogodkov glede varnosti in učinkovitosti sunitiniba pri pediatričnih bolnikih z GIST (starostna skupina 6-17 let).
A population PK model based on sparse sampling determined that levofloxacin serum concentrations were comparable between paediatric and adult patients following 28 days of treatment.
Na modelu populacijske FK na podlagi redkih vzorcev so ugotovili, da so bile koncentracije levofloksacina v serumu po 28 dneh zdravljenja med pediatričnimi in odraslimi bolniki primerljive.